北京万泰生物药业股份有限公司 信息披露管理制度 北京万泰生物药业股份有限公司 信息披露管理制度 二〇二五年十一月 北京万泰生物药业股份有限公司 信息披露管理制度 北京万泰生物药业股份有限公司 信息披露管理制度 （2025 年 11 月修订） 第一章 总则 第一条 为确保北京万泰生物药业股份有限公司（以下简称"公司"）信 息披露的及时、准确、充分、完整，保护投资者合法权益，根据《中华人民共和 国公司法》《中华人民共和国证券法》（以下简称"《证券法》"）等有关法律 法规及《北京万泰生物药业股份有限公司章程》（以下简称"《公司章程》"）， 结合公司实际情况，制定本制度。 第二条 本制度所称"信息披露"，是当有需要定期披露的信息、发生或 即将发生可能对公司证券及其衍生品种的交易价格产生较大影响的信息（以下简 称"重大信息"）时，根据法律、行政法规、部门规章和其他有关规定及时将相 关信息的公告文稿和相关备查文件报送上海证券交易所（以下简称"上交所"） 登记，并在中国证监会指定的媒体发布。 第三条 本制度适用于如下人员和机构等相关信息披露义务人的信息披 露行为： 第二章 信息披露的基本原则和一般规定 第四条 信息披露义务 ...

北京万泰生物药业股份有限公司 董事、高级管理人员所持公司股份及其变动管理制度 北京万泰生物药业股份有限公司 董事、高级管理人员所持公司股份及其 变动管理制度 二〇二五年十一月 北京万泰生物药业股份有限公司 董事、高级管理人员所持公司股份及其变动管理制度 北京万泰生物药业股份有限公司 董事、高级管理人员所持公司股份及其变动管理制度 （2025 年 11 月修订） 第一章 总则 第一条 为加强对北京万泰生物药业股份有限公司（以下简称"公司"或 "本公司"）董事、高级管理人员等主体所持本公司股份及其变动的管理，根据 《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券 法》（以下简称"《证券法》"）《上市公司董事和高级管理人员所持本公司股 份及其变动管理规则》等法律、法规、规范性文件以及《上海证券交易所股票上 市规则》《北京万泰生物药业股份有限公司章程》（以下简称"《公司章程》"） 等有关规定，结合公司实际情况，制定本制度。 第二条 公司董事、高级管理人员在买卖本公司股票及其衍生品种前，应 知悉《公司法》《证券法》等法律、法规、规范性文件关于内幕交易、短线交易、 操纵市场等禁止行为的规定，不得进行 ...

证券代码：603392 证券简称：万泰生物 公告编号：2025-058 北京万泰生物药业股份有限公司 关于取消监事会并修订《公司章程》的公告 根据《中华人民共和国公司法》《上市公司章程指引》以及《上海证券交易 所股票上市规则》等相关法律法规、规范性文件的最新规定，结合公司实际情况， 公司将不再设置监事会，监事会的相关职权由董事会审计委员会行使，同时《监 事会议事规则》等监事会相关制度相应废止。 在公司股东会审议通过取消监事会事项之前，公司第六届监事会仍将严格按 照有关法律、法规和《公司章程》的规定继续履行监督职能，维护公司和全体股 东利益。 二、修订《公司章程》情况 根据《中华人民共和国公司法》《上市公司章程指引》《上海证券交易所股 票上市规则》等法律法规和规范性文件的规定，结合公司实际情况，拟对现行《公 司章程》进行修订，具体修订内容如下： | 原《北京万泰生物药业股份有限公司 | 修订后《北京万泰生物药业股份有限公司章 | | --- | --- | | 章程》条款 | 程》条款 | | 第十一条 本公司章程自生效之日起，即 | 第十一条 本公司章程自生效之日起，即 | | --- | --- | | 成 ...

证券代码：603392 证券简称：万泰生物 公告编号：2025-059 北京万泰生物药业股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东会类型和届次 2025年第二次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 11 月 28 日 14 点 00 分 召开地点：北京市昌平区科学园路 31 号公司会议室 (五)网络投票的系统、起止日期和投票时间。 股东会召开日期：2025年11月28日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 11 月 28 日 至2025 年 11 月 28 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9: ...

一、监事会会议召开情况 北京万泰生物药业股份有限公司（以下简称"公司"）于2025年11月12日以 通讯方式召开第六届监事会第十二次会议。根据《公司章程》和公司《监事会议 事规则》的有关规定，本次会议豁免通知时限要求，公司于2025年11月11日以专 人送达、电话等方式通知全体监事。本次会议由公司监事会主席邢庆超先生主持， 应出席监事3人，实际出席监事3人。本次会议的出席人数、召开和表决方式符合 《公司法》等法律、法规及《公司章程》的相关规定，合法有效。 证券代码：603392 证券简称：万泰生物 公告编号：2025-057 北京万泰生物药业股份有限公司 第六届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、监事会会议审议情况 1、审议通过了《关于取消监事会并修订<公司章程>的议案》 根据《中华人民共和国公司法》《上市公司章程指引》以及《上海证券交易 所股票上市规则》等相关法律法规、规范性文件的最新规定，结合公司实际情况， 同意公司不再设置监事会，监事会的相关职权由董事会审计委员会行使，同时《监 ...

证券代码：603392 证券简称：万泰生物 公告编号：2025-056 北京万泰生物药业股份有限公司 第六届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 北京万泰生物药业股份有限公司（以下简称"公司"）于2025年11月12日以 通讯方式召开第六届董事会第十二次会议。根据《公司章程》和公司《董事会议 事规则》的有关规定，本次会议豁免通知时限要求，公司于2025年11月11日以专 人送达、电话等方式通知全体董事。本次会议由公司董事长邱子欣先生主持，应 出席董事7人，实际出席董事7人。本次会议的出席人数、召开和表决方式符合《 公司法》等法律、法规及《公司章程》的相关规定，合法有效。 二、董事会会议审议情况 1、审议通过了《关于取消监事会并修订<公司章程>的议案》 根据《中华人民共和国公司法》《上市公司章程指引》以及《上海证券交易 所股票上市规则》等相关法律法规、规范性文件的最新规定，结合公司实际情况， 同意公司不再设置监事会，监事会的相关职权由董事会审计委员会行使，同时《监 事 ...

Core Insights - The Zhongguancun Life Science Park has transformed into a vital axis for Beijing's international technology innovation center, evolving from rural areas into a hub for life sciences and biotechnology [1][3] - The park is home to over 600 innovative pharmaceutical companies, creating a vibrant ecosystem that includes leading enterprises, innovative SMEs, supportive policies, and capital [1][2] Group 1: Innovation Ecosystem - The park features a comprehensive innovation chain that encompasses basic research, technology development, clinical validation, and production [2][3] - Key institutions such as the National Protein Science Center and various top-tier research institutes are located within the park, facilitating significant advancements in life sciences [2][3] - The park has produced notable innovations, including China's first billion-dollar drug and several cutting-edge gene editing tools recognized internationally [3][4] Group 2: Entrepreneurial Environment - The park has become a "paradise for scientists" where many researchers have founded their own companies, with 112 enterprises established by scientists [5][6] - Early support for scientific entrepreneurship is a unique attraction of the park, providing essential resources and funding for startups [6][7] - The park's strong industry cluster effect allows scientists to easily find partners and resources, significantly lowering the barriers to entrepreneurship [7][8] Group 3: Financial Support and Investment - The Beijing government has established a 20 billion yuan investment fund to support the pharmaceutical and health industry, ensuring financial backing for innovation [7][8] - The park's management has created a multi-layered investment fund matrix, collaborating with over 50 market-oriented investment funds to empower original innovations [8][9] Group 4: Future Development - The park aims to maintain its leading position in emerging fields such as cell and gene therapy, with ongoing projects and clinical trials [3][9] - The construction of third-party service platforms and technology centers is crucial for accelerating innovation and enhancing industry competitiveness [9][10] - The park is focused on expanding its global influence in the biopharmaceutical sector, with a commitment to fostering original discoveries that benefit the world [12]

Core Insights - The Beijing Zhongguancun Life Science Park has transformed into a vital axis for Beijing's international technology innovation center, becoming a key base for life sciences, biotechnology, and new pharmaceutical industries in China [1][3] - The park has developed a vibrant industrial ecosystem with hundreds of pharmaceutical companies, supported by favorable policies and capital, creating a "biopharmaceutical rainforest" [1][3] Innovation Chain - The park features a comprehensive innovation chain that includes basic research, technology development, clinical validation, and production sales, exemplified by institutions like the National Protein Science Center [2][3] - Key research institutions and hospitals within the park facilitate the transition from scientific discovery to practical applications in medicine [2] Industry Ecosystem - Over 600 innovative pharmaceutical companies, including BeiGene and Innovent Biologics, are located in the park, focusing on transforming research findings into potential new drug candidates [3][4] - The park has evolved from being policy-driven to a self-driven industry ecosystem, showcasing a mature life sciences innovation environment [3] Achievements and Recognition - The park has produced significant innovations, including China's first billion-dollar drug, Zebutine, and has been recognized as the top life sciences park in China according to a report by the China Biotechnology Development Center [4][8] - The park's unique advantages include a strong industrial foundation, natural clustering effects, and a complete industrial chain, supported by top research institutions and talent reserves in Beijing [4] Entrepreneurial Environment - The park is described as an "ideal paradise" for scientists, with many researchers becoming entrepreneurs, leading to the establishment of 112 companies founded by scientists [5][6] - The support for early-stage scientific entrepreneurship is a key attraction of the Zhongguancun Life Science Park, providing essential resources and funding [6][7] Funding and Investment - The Beijing government has established a 20 billion yuan pharmaceutical health industry investment fund to support the development of the industry [8] - The park's operational platform has partnered with over 50 market-oriented investment funds, investing in 468 pharmaceutical health projects to empower original innovations [8] Future Development - The 2024 Beijing Action Plan emphasizes the importance of building research hospitals and accelerating the construction of the Zhongguancun Life Science Park's third phase to enhance its global competitiveness [9][10] - The park aims to maintain its leading position in emerging fields such as cell and gene therapy, with a focus on platform construction to support industry development [10][12]

Core Viewpoint - The inclusion of the HPV vaccine in China's national immunization program starting from November 10, 2025, will allow eligible residents to receive the vaccine for free, significantly enhancing public health efforts against cervical cancer and related diseases [1][2][4]. Group 1: Policy and Implementation - The HPV vaccine will be provided free of charge to girls born on or after November 10, 2011, who are 13 years old, with a recommended two-dose schedule [4][6]. - The addition of the HPV vaccine increases the total number of vaccines in the national immunization program to 15, which aims to improve vaccination rates and public health [2][4]. Group 2: Market Impact - The procurement price of the bivalent HPV vaccine has decreased significantly, with a reported price of 86 yuan per dose in March 2024 and a budgeted price of 27.5 yuan per dose for 2025 [5]. - The government’s centralized procurement is expected to drive a substantial increase in HPV vaccine sales and market penetration, benefiting companies like Watson Bio, which has sufficient production capacity to meet demand [5][6]. Group 3: Health Benefits and Efficacy - Vaccination can prevent over 70% of cervical cancer cases and reduce the incidence of other HPV-related diseases, as evidenced by experiences from other countries [4][6]. - Research indicates that girls aged 9-14 produce antibody levels more than twice that of those over 15 when vaccinated, making this age group a strategic target for vaccination [6][9]. Group 4: Vaccine Options and Recommendations - There are three types of HPV vaccines available: bivalent, quadrivalent, and nonavalent, with the nonavalent vaccine providing the broadest protection against various HPV strains [7][9]. - The guidelines suggest that women who have completed the bivalent or quadrivalent vaccination do not need to receive the nonavalent vaccine unless they choose to do so based on personal circumstances [9].

Macro Strategy - In October, China's exports showed a year-on-year decline of -1.10%, marking the first negative growth since March 2025, which affected the cumulative year-on-year growth rate, decreasing from 6.10% in September to 5.30% in October. This decline is attributed to a high base in October 2024 and a temporary escalation in trade conflicts between China and the US in early October 2025 [3][4]. Market Overview - From November 3 to November 7, 2025, A-share indices experienced wide fluctuations, with the Shanghai Composite Index rising by 1.08% and the ChiNext Index increasing by 0.65%. The market is expected to continue a "slow bull" trend with wide fluctuations in November due to reduced short-term trade conflict risks between China and the US [4][5]. - Among the 31 first-level industries, the top performers were electric equipment and coal, with weekly increases of 4.98% and 4.52%, respectively. Conversely, the beauty care and computer sectors saw declines of -3.10% and -2.54% [6][7]. North Exchange Market - As of November 7, 2025, the North Exchange had 282 listed stocks, with an average total market value of 908.24 billion yuan, reflecting a 1.24% increase from the previous week. The liquidity decreased, with average trading volume dropping by 17.23% [11][12]. - The highest weekly gain was recorded by Danna Biological, which surged by 377.78% in its first week of trading, while the largest decline was seen in Beiyikang, which fell by 12.35% [13]. Vaccine Industry - The vaccine industry is experiencing structural differentiation, with companies like Kangtai Biological and Zhonghui Biological making significant advancements in vaccine development for specific populations, such as infants and pregnant women. The updated technical guidelines emphasize the importance of vaccination for high-risk groups [17][21]. - The vaccine sector's performance remains under pressure, with a year-to-date decline of -1.57%. The industry is focusing on innovation and international expansion to navigate current challenges [19][21]. - The vaccine sector's price-to-earnings ratio (PE) is currently at 99.07X, reflecting a decrease of 4.97X from the previous week, while the price-to-book ratio (PB) remains stable at 1.94X [20]. Investment Recommendations - The vaccine industry is advised to focus on innovation and international markets, as the current market conditions present challenges due to supply-demand imbalances and intense competition. Companies with strong technological capabilities and differentiated product lines are recommended for investment [21][23].